News | FDA | April 29, 2024

Elekta Instrument AB recalls disposable biopsy needle kit for Leksell Stereotactic System for possibly containing microscopic stainless steel debris on the inside of the biopsy needle

Elekta Instrument AB recalls disposable biopsy needle kit for Leksell Stereotactic System for possibly containing microscopic stainless steel febris on the inside of the biopsy needle

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable Biopsy Needles (911933) from one batch (837838839) which can contain some microscopic stainless steel debris on the inside of the biopsy needle. The presence of debris in biopsy samples can hinder examination and delay the process. Moreover, there's a risk of debris being deposited in the brain, which could affect future MRI scans, potentially rendering them useless or unobtainable.

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Recalled Product

  • Product Names: Disposable Biopsy Needles (911933)
  • Product Codes: HAW
  • Lot Number: 837838839
  • Distribution Dates: August 29, 2023 to January 5, 2024
  • Devices Recalled in the U.S.: 10
  • Date Initiated by Firm: March 15, 2024

Device Use

The Leksell Stereotactic System helps doctors locate and diagnose brain disorders. The Disposable Biopsy Needle Kit is used in neurosurgery for precise brain tissue sampling. It's designed for use with the Leksell Stereotactic System, allowing surgeons to obtain tissue samples accurately and minimally invasively.

Reason for Recall

Elekta Instrument AB is recalling Disposable Biopsy Needles (911933) from one batch (837838839) which can contain some microscopic stainless steel debris on the inside of the biopsy needle. The material in the debris is stainless steel, the same material as the biopsy needle.

If debris on the inside of the biopsy needle comes loose, it may appear in the biopsy sample and delay or make examination difficult. There is also a potential risk of debris being deposited in the brain. The long term functional consequences of such particles in the brain are unknown. If this occurs, the metallic debris could cause future MRI scans of the brain to be useless or even unable to be obtained. This is a serious negative consequence in a patient with a brain tumor who will require brain MRI surveillance scans for life, with no alternative available.

There have been no reported injuries and no reports of death associated with this issue.

Who May be Affected

  • Health care professionals, specifically specialists in brain disorders, who use the Disposable Biopsy Needle Kit and Leksell Stereotactic System
  • People receiving care using the Disposable Biopsy Needle Kit and Leksell Stereotactic System

What to Do

On March 15, 2024, Elekta sent all affected customers an Urgent Recall Notification.

The letter requested customers to:

  • Remove and dispose all Disposable Biopsy Needles (911933) from batch 837838839.
    • Contact the local Elekta representative for ordering replacement needle kits.
  • Post this notice in a place accessible to all users and advise appropriate personnel.
  • Complete the included Acknowledge Form and return it to Elekta.

Contact Information

Customers in the U.S. with questions about this recall should contact Elekta Instrument AB at (855) 693-5358.

Additional Resources

How do I report a problem?

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX.


Related Content

News | Computed Tomography (CT)

March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...

Time March 09, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | HIMSS

March 3, 2026 — MedDream will present its cloud-native, AI-ready universal DICOM viewer in the Amazon Web Services (AWS) ...

Time March 03, 2026
arrow
News

Feb. 26, 2026 — GE HealthCare and UCSF Health have announced a 10-year Care Alliance collaboration focused on ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | Contrast Media

Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...

Time February 24, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
Subscribe Now